This inventor holds 8 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Genzyme Corporation. Active years: 2008-2024.
Location History:
- Boston, MA (US) (2008)
- Somerville, MA (US) (2017 - 2023)
Company Filing History:
Years Active: 2008-2024
Title: Diego A Gianolio: Innovator in Antibody-Drug Conjugation
Introduction
Diego A Gianolio is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. With a total of 8 patents to his name, Gianolio's work has the potential to revolutionize therapeutic approaches in medicine.
Latest Patents
Gianolio's latest patents include groundbreaking innovations such as "Site-specific antibody-drug conjugation through glycoengineering." This patent provides binding polypeptides, including antibodies, and effector moiety conjugates, which feature a site-specifically engineered drug-glycan linkage. The technology encompasses nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors, and host cells for their production. Additionally, he has developed a patent for "Hyperglycosylated binding polypeptides," which includes binding polypeptides with engineered N-linked glycosylation sites. These advancements offer methods for using antigen-binding polypeptides to treat various diseases.
Career Highlights
Diego A Gianolio is currently associated with Genzyme Corporation, where he continues to push the boundaries of innovation in biotechnology. His work focuses on enhancing the efficacy of therapeutic agents through advanced glycoengineering techniques. His contributions have been instrumental in the development of novel treatments that target specific diseases.
Collaborations
Gianolio has collaborated with notable professionals in his field, including Huawei Qiu and Pradeep K Dhal. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the impact of their collective work.
Conclusion
Diego A Gianolio stands out as a key figure in the field of biotechnology, with a focus on antibody-drug conjugates and glycoengineering. His innovative patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.